Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
REGN or TECH: Which Is the Better Value Stock Right Now?
01:27pm, Friday, 08'th Oct 2021
REGN vs. TECH: Which Stock Is the Better Value Option?
Should Value Investors Buy Regeneron (REGN) Stock?
01:27pm, Friday, 08'th Oct 2021
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Regeneron (REGN) Stock Sinks As Market Gains: What You Should Know
07:19pm, Wednesday, 06'th Oct 2021
Regeneron (REGN) closed at $546.57 in the latest trading session, marking a -0.79% move from the prior day.
Will Regeneron Stock See Lower Levels After Merck's Positive Data?
10:00am, Tuesday, 05'th Oct 2021
The stock price of Regeneron has seen a 16% fall over the last twenty-one trading days, while it is down 6% over the last year. The volatility in REGN stock is being driven by the developments for
Regeneron Pharmaceuticals: Undervalued Cash Generating Machine
01:03pm, Monday, 04'th Oct 2021
Regeneron Pharmaceuticals: Undervalued Cash Generating Machine
Here's Why Regeneron (REGN) is Poised for a Turnaround After Losing 16% in 4 Weeks
11:49am, Monday, 04'th Oct 2021
Regeneron (REGN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates
REGN Stock Price: Why It Fell Over 5%
02:55pm, Saturday, 02'nd Oct 2021
The stock price of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) fell by over 5% in the previous trading session. This is why it happened.
Is Regeneron Pharmaceuticals (REGN) Outperforming Other Medical Stocks This Year?
02:02pm, Friday, 01'st Oct 2021
Is (REGN) Outperforming Other Medical Stocks This Year?
Core PCE Inflation Stays at Record-High in August
12:27pm, Friday, 01'st Oct 2021
Core PCE Inflation Stays at Record-High in August.
Regeneron (REGN) Reports Positive Data on Antibody Cocktail
10:09am, Friday, 01'st Oct 2021
Regeneron's (REGN) phase III study assessing REGEN-COV in patients hospitalized with COVID-19 meets its primary goal.
Regeneron-Roche Post Encouraging New Data For COVID-19 Antibody Cocktail
07:15am, Thursday, 30'th Sep 2021
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Roche Holdings AG (OTC: RHHBY) announced positive data from Phase 2/3 2066 study of Ronapreve (casirivimab and imdevimab) or REGN-COV in hospitali
New REGEN-COV™ (casirivimab and imdevimab) Data Show Supportive Results in Patients Hospitalized with COVID-19
01:00am, Thursday, 30'th Sep 2021
TARRYTOWN, N.Y., Sept. 30, 2021 /PRNewswire/ -- Trial met primary endpoint, showing REGEN-COV significantly reduced viral load within 7 days of treatment; trial conducted in patients hospitalized wi
New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV™ (casirivimab and imdevimab) to Treat COVID-19
05:00pm, Wednesday, 29'th Sep 2021
TARRYTOWN, N.Y., Sept. 29, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the New England Journal of Medicine (NEJM) published positive detailed results
7 Biotech Stocks Entering the Golden Boom Phase
03:30pm, Tuesday, 28'th Sep 2021
These biotech stocks offer a more mature take on an otherwise risky sector. These companies already have successes under their belt.
Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Cantor Fitzgerald Virtual Global Healthcare 2021 Conference (Transcript)
